Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says

MT Newswires Live01-11

Guardant Health (GH) has an "underappreciated" catalyst path as the company's colorectal cancer screening tool has a "greater commercial opportunity" than previously expected, UBS said in a note emailed Friday.

The firm said it was more constructive on genomics application companies versus genomics technology companies in 2025 and that Guardant was its top pick within the group.

UBS said that a survey of physicians indicated that blood-based colorectal cancer screening tools could amount to around 10% of market share in the next one to two years, more than twice the consensus forecasts. This could be a catalyst for Guardant's Shield colorectal cancer screening tool, alongside pricing upside and medical society guidelines, according to UBS.

UBS also struck a positive tone on Natera (NTRA) which it said should continue to ramp volumes for its cancer screening tool Signatera, as well as a "positive growth trajectory" for Veracyte (VCYT).

Price: 36.78, Change: +0.19, Percent Change: +0.52

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502811748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-11 04:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502811748","market":"sh","top_or_hot":-1,"title":"Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Guardant Health (GH) has an \"underappreciated\" catalyst path as the company's colorectal cancer screening tool has a \"greater commercial opportunity\" than previously expected, UBS said in a note emailed Friday.</p><p>The firm said it was more constructive on genomics application companies versus genomics technology companies in 2025 and that Guardant was its top pick within the group.</p><p>UBS said that a survey of physicians indicated that blood-based colorectal cancer screening tools could amount to around 10% of market share in the next one to two years, more than twice the consensus forecasts. This could be a catalyst for Guardant's Shield colorectal cancer screening tool, alongside pricing upside and medical society guidelines, according to UBS.</p><p>UBS also struck a positive tone on Natera (NTRA) which it said should continue to ramp volumes for its cancer screening tool Signatera, as well as a \"positive growth trajectory\" for Veracyte (VCYT).</p><p>Price: 36.78, Change: +0.19, Percent Change: +0.52</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health Holds 'Underappreciated' Catalyst Path, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-11 04:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Guardant Health (GH) has an \"underappreciated\" catalyst path as the company's colorectal cancer screening tool has a \"greater commercial opportunity\" than previously expected, UBS said in a note ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502811748","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502811748","pubTimestamp":1736539973,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guardant Health  has an \"underappreciated\" catalyst path as the company's colorectal cancer screening tool has a \"greater commercial opportunity\" than previously expected, UBS said in a note emailed Friday.The firm said it was more constructive on genomics application companies versus genomics technology companies in 2025 and that Guardant was its top pick within the group.UBS said that a survey of physicians indicated that blood-based colorectal cancer screening tools could amount to around 10% of market share in the next one to two years, more than twice the consensus forecasts. This could be a catalyst for Guardant's Shield colorectal cancer screening tool, alongside pricing upside and medical society guidelines, according to UBS.UBS also struck a positive tone on Natera  which it said should continue to ramp volumes for its cancer screening tool Signatera, as well as a \"positive growth trajectory\" for Veracyte .Price: 36.78, Change: +0.19, Percent Change: +0.52","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc.","VCYT":"Veracyte Inc","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4196":"保健护理服务","BK4535":"淡马锡持仓","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4588":"碎股","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","GH":"Guardant Health Inc.","BK4551":"寇图资本持仓","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD"},"translate_title":"瑞银表示，Guardant Health拥有“未被充分重视”的催化剂路径","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":0.9,"NTRA":0.9,"GH":0.9},"content_text":"Guardant Health (GH) has an \"underappreciated\" catalyst path as the company's colorectal cancer screening tool has a \"greater commercial opportunity\" than previously expected, UBS said in a note emailed Friday.The firm said it was more constructive on genomics application companies versus genomics technology companies in 2025 and that Guardant was its top pick within the group.UBS said that a survey of physicians indicated that blood-based colorectal cancer screening tools could amount to around 10% of market share in the next one to two years, more than twice the consensus forecasts. This could be a catalyst for Guardant's Shield colorectal cancer screening tool, alongside pricing upside and medical society guidelines, according to UBS.UBS also struck a positive tone on Natera (NTRA) which it said should continue to ramp volumes for its cancer screening tool Signatera, as well as a \"positive growth trajectory\" for Veracyte (VCYT).Price: 36.78, Change: +0.19, Percent Change: +0.52","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502811748"}